Details for 2020807561

Up to date per 24.05.2026

Actions

Title / Product Name

KOMBINATION SUBSTITUIERTEN 4-AMINOISOINDOLIN-1,3-DIONVERBINDUNGEN UND ZWEITEN WIRKSTOFFE ZUR VERWENDUNG BEI DER BEHANDLUNG EINER HÄMATOLOGISCHEN MALIGNITÄT

Status

Granted/Registered

Protection Type

European Patent

(AT-) Application Number

2020807561

EP Publication Number

4048260

E-Number

1895762

Language

PCT Number

US20056439

Publication Date

31.08.2022 A

11.03.2026 B1

Registration Date

11.03.2026

AT Publication Date

15.04.2026

Application Date

20.10.2020

Registration Number

Priorities

21.10.2019

201962923945 P

IPC

A61K 31/4045 20060101AFI20210430BHEP

Maximum Duration of Protection

20.10.2040

Owner

Celgene CorporationRoute 206 & Province Line Road Princeton, NJ 08543US

Representative

No representatives present

Inventor

ANTON, Maria Soraya Carrancioc/o Signal Pharmaceuticals, LLC 10300 Campus Point Drive, Suite 100 San Diego, CA 92121US

BUCHHOLZ, Tonia J.c/o Celgene Corporation 1500 Owens Street, Suite 600 San Francisco, CA 94185US

CHANG, Henryc/o Celgene Corporation 1500 Owens Street, Suite 600 San Francisco, CA 94185US

FILVAROFF, Ellenc/o Celgene Corporation 1500 Owens Street, Suite 600 San Francisco, CA 94185US

KASIBHATLA, Shailajac/o Signal Pharmaceuticals, LLC 10300 Campus Point Drive, Suite 100 San Diego, CA 92121US

LOPEZ-GIRONA, Antoniac/o Signal Pharmaceuticals, LLC 10300 Campus Point Drive, Suite 100 San Diego, CA 92121US

MOHAN, Adithic/o Celgene Corporation 1500 Owens Street, Suite 600 San Francisco, CA 94185US

NARLA, Rama Krishnac/o Signal Pharmaceuticals, LLC 10300 Campus Point Drive, Suite 100 San Diego, CA 92121US

POURDEHNAD, Michaelc/o Celgene Corporation 1500 Owens Street, Suite 600 San Francisco, CA 94185US

PIERCEALL, William EdwardCelgene Summit West 556 Morris Avenue Summit, NJ 07901US

THAKURTA, AnjanCelgene Summit West 556 Morris Avenue Summit, NJ 07901US

Information about Fees